Chemotherapy News and Research

Latest Chemotherapy News and Research

FBH1 gene helps turn up the effect of chemotherapy

Chemotherapy is one of the most common treatments for cancer patients. However, many patients suffer from serious side-effects and a large proportion does not respond to the treatment. Researchers from the Biotech Research and Innovation Centre (BRIC) and Center for Healthy Aging, University of Copenhagen, now show that the gene FBH1 helps turn up the effect of chemotherapy.

30 Jan 2013

Phenformin decreases size of lung tumors and increases survival in mice

Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.

30 Jan 2013

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

Health industry shows stock market muscle

Despite various concerns and challenges, health care stocks, including shares of for-profit hospitals, have fared well in the opening weeks of 2013.

29 Jan 2013

New genetic test can help identify small aggressive lung tumors linked with poor survival

A novel genetic test can help identify small but aggressive lung tumors associated with poor survival, according to a study released today at the 49th Annual Meeting of The Society of Thoracic Surgeons held at the Los Angeles Convention Center.

29 Jan 2013

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

What did Pope John Paul II, Ronald Reagan and Robin Gibb of the Bee Gees have in common? Each was diagnosed with colorectal cancer, the third most commonly diagnosed cancer in the world and the fourth most common cause of cancer death.

29 Jan 2013

Blue light can selectively eradicate skin and soft tissue infections

Blue light can selectively eradicate Pseudomonas aeruginosa infections of the skin and soft tissues, while preserving the outermost layer of skin, according to a proof-of-principle study led by Michael R. Hamblin of the Massachusetts General Hospital, and the Harvard Medical School, Boston.

29 Jan 2013

KLF8 protein could be helpful in preventing cancer recurrence

Just as the body can become resistant to antibiotics, certain methods of killing cancer tumors can end up creating resistant tumor cells. But a University of Central Florida professor has found a protein present in several types of cancer, including breast and ovarian cancer, which could be helpful in preventing tumors from coming back.

29 Jan 2013

Meridian reports positive pre-IND meeting with FDA for ML061

Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.

29 Jan 2013

European radiotherapy provision has ‘significant shortfalls’

A review published in The Lancet Oncology reveals significant shortfalls in radiotherapy equipment and manpower across Europe.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

New method allows controlled release of drugs; could help develop targeted treatments

Researchers have discovered a method that allows for the controlled release of an active agent on the basis of a magnetic nanovehicle.

25 Jan 2013

New study may help treat patients with multiple myeloma

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

25 Jan 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

FBH1 gene helps turn up the effect of chemotherapy

Phenformin decreases size of lung tumors and increases survival in mice

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Health industry shows stock market muscle

New genetic test can help identify small aggressive lung tumors linked with poor survival

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

Blue light can selectively eradicate skin and soft tissue infections

KLF8 protein could be helpful in preventing cancer recurrence

Meridian reports positive pre-IND meeting with FDA for ML061

European radiotherapy provision has ‘significant shortfalls’

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

HDL cholesterol key to fighting lymphoma

New method allows controlled release of drugs; could help develop targeted treatments

New study may help treat patients with multiple myeloma

Study highlights the need for more targeted antibiotic therapy in cancer patients

Breast cancer screening: Benefits outweigh deaths due to adverse treatment

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in